Dynamics of IGF-1R expression during endocrine breast cancer treatment

Molecular Imaging and Biology

Volumn 16, Issue 4, 2014, Pages 529-537

  Heskamp, Sandra ^a   Boerman, Otto C ^a   Molkenboer Kuenen, Janneke D M ^a   Koornstra, Rutger H T ^a   Linn, Sabine C ^b   Oyen, Wim J G ^a   Van Der Graaf, Winette T A ^a   Van Laarhoven, Hanneke W M ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Breast cancer; ER; Estradiol; IGF 1R; SPECT; Tamoxifen

Indexed keywords

ESTRADIOL; INDIUM 111; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; MONOCLONAL ANTIBODY; R-1507 MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HORMONAL THERAPY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BREAST NEOPLASMS; CELL MEMBRANE; DRUG EFFECTS; DRUG SCREENING; HUMAN; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL MEMBRANE; ESTRADIOL; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; MIDDLE AGED; RECEPTOR, IGF TYPE 1; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904410600     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0723-6     Document Type: Article

References (36)

1. Hartog H, Wesseling J, Boezen HM, van der Graaf WT (2007) The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 43:1895-1904 (Pubitemid 47284866)
2. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20-47 (Pubitemid 46220849)
3. Poulikakos PI, Persaud Y, Janakiraman M et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-390
4. Railo MJ, von Smitten K, Pekonen F (1994) The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A:307-311 (Pubitemid 24152469)
5. Yerushalmi R, Gelmon KA, Leung S et al (2011) Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 132:131-142
6. Lee AV, Jackson JG, Gooch JL et al (1999) Enhancement of insulinlike growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. MolEndocrinol 13:787-796 (Pubitemid 30645331)
7. Maor S, Mayer D, Yarden RI et al (2006) Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. JEndocrinol 191:605-612 (Pubitemid 46210286)
8. Santen RJ, Fan P, Zhang Z et al (2009) Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 74:586-594
9. Fagan DH, Yee D (2008) Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13:423-429
10. Cao L, Yu Y, Darko I et al (2008) Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68:8039-8048
11. Zha J, O'Brien C, Savage H et al (2009) Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 8:2110-2121
12. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4:806-813 (Pubitemid 39331152)
13. Jain RK (1999) Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1:241-263
14. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD et al (2010) ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med 51:1565-1572
15. Brom M, Joosten L, Oyen WJ et al (2012) Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with 111In in HEPES and MES buffer. EJNMMI Res 2:4
16. van der Have F, Vastenhouw B, Ramakers RM et al (2009) U-SPECTII: an ultra-high-resolution device for molecular small-animal imaging. J Nucl Med 50:599-605
17. Kaufman PA, Ferrero JM, Bourgeois H et al (2010) Abstract S1-4: a randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res 70:S1-S4
18. Fagan DH, Uselman RR, Sachdev D, Yee D (2012) Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 72:3372-3380
19. Drury SC, Detre S, Leary A et al (2011) Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocrine-related Cancer 18:565-577
20. Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC et al (2011) Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res 17:7693-7703
21. Asmane I, Watkin E, Alberti L et al (2012) Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer 48:3027-3035
22. Huang F, Greer A, Hurlburt W et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/ HER2 inhibitors. Cancer Res 69:161-170
23. Jain RK (1987) Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6:559-593
24. Van der Veldt AA, Lubberink M, Bahce I et al (2012) Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21:82-91
25. Heskamp S, Boerman OC, Molkenboer-Kuenen JD, et al. (2013) Bevacizumab reduces tumor targeting of anti-epidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer 133:307-314
26. Bogin L, Degani H (2002) Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res 62:1948-1951 (Pubitemid 34408435)
27. Ruohola JK, Valve EM, Karkkainen MJ et al (1999) Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 149:29-40 (Pubitemid 29236221)
28. Garvin S, Dabrosin C (2003) Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 63:8742-8748 (Pubitemid 38064052)
29. Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28:3009-3021
30. Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800-5807
31. Pappo AS, Patel SR, Crowley J et al (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29:4541-4547
32. Ramalingam SS, Spigel DR, Chen D et al (2011) Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 29:4574-4580
33. Watkins DJ, Tabernero J, Schmoll H, et al. (2011) A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in chemorefractory metastatic colorectal cancer (mCRC) with wilde-type (wit) KRAS status. J Clin Oncol 29:S3515
34. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, et al. (2012) Optimization of IGF-1R SPECT/CT imaging using (111)In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507. Mol Pharm 9:2314-2321
35. Cornelissen B, McLarty K, Kersemans V, Reilly RM (2008) The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 35:645-653
36. Tolmachev V,Malmberg J, Hofstrom C et al (2012) Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the Affibody molecule 111In-DOTA-ZIGF1R:4551. J Nucl Med 53:90-97